Upsher-Smith’s newly opened facility is located in Minnesota, US, and covers 270,000-square-feet. The manufacturing space will provide packaging and serialization, as well as supporting contract manufacturing of clients’ products.
The company will also use the site’s capacity to manufacture its own products. In terms of what types of products will be produced at the site, Upsher-Smith stated that it offers solvent and aqueous-based oral solid doses, in tablet or capsule form, powders, liquids, and suspensions.
In addition, the serialized packaging solutions include OSD/liquid bottles, unit dose blisters and liquid cups, and powder filling in sachets, bottles, and cans. The company noted that outbound packaging configurations are aggregated in accordance with the pending Drug Supply Chain Security Act.
Rich Fisher, president and COO, Upsher-Smith, said, “The opening of this world-class facility marks another important milestone for our company. We plan to use this innovative asset to support our own organic production and pipeline as well as partners looking for end-to-end supply chain solutions in the contract manufacturing space.”
The Grove Park facility is also the base for the company’s corporate headquarters, and the manufacturing plant adds to the other locations in the company’s US network, which includes locations in Plymouth, Minnesota, Denver, Colorado, and Morristown, New Jersey. Upsher-Smith stated that the geographical location of the new facility would allow the company to offer “controlled costs” to clients.
The space is known as Plant C, and Upsher-Smith will relocate all of its packaging work to the site, as well as transferring all of the company’s manufacturing projects to the site. This encompasses its own internal portfolio, external development projects, and contract manufacturing partnerships.
Last year, Upsher-Smith signed a strategic partnership with Emphascience to support the development of a specialty branded generic product.
The company stated at the time that the collaboration was part of the company’s strategy to grow its portfolio of products through partnerships and product acquisitions. Fisher stated that the move to grow its portfolio of products would also “drive volume to our new manufacturing facility.”
Beyond the new facility and its capabilities, the company also has a pilot plant, Plant B, located nearby, which is also able to manufacture small, commercial batches of product that are destined for US Food and Drug Administration (FDA) submissions and for clinical purposes.
